Objectives: This study compared the osteogenic mechanisms and preclinical efficacy of bone morphogenetic protein 9 (BMP9) and BMP2 in vitro and in a beagle peri‐implant defect model in vivo. Materials and Methods: In vitro, MC3T3‐E1 preosteoblasts were treated with BMP2 or BMP9 to assess osteogenic gene expression ( Col1, Runx2, Alp, Ocn ) by real‐time PCR, Smad1/5/9 phosphorylation by western blotting, and osteogenesis by alkaline phosphatase (ALP) and Alizarin Red S staining. In vivo, saddle‐type peri‐implant defects were created in beagle mandibles and treated with a collagenated xenograft matrix with or without BMP2 or BMP9 (150 μg/site). After 8 weeks, implant stability, micro‐CT, histomorphometry, and osseointegration parameters were analyzed. Results: BMP9 significantly enhanced osteogenic gene expression, Smad1/5/9 phosphorylation, ALP activity, and mineralization compared to BMP2. In vivo, BMP9 yielded the highest implant stability values, greater defect fill, and higher bone volume fraction, bone mineral density, and bone‐to‐implant contact. Conclusions: BMP9 showed stronger osteoinductive potential than BMP2, resulting in improved bone regeneration and osseointegration. These findings suggest that BMP9 is a promising growth factor for improving dental implant outcomes.